NICE publish further draft guidance on lecanemab and donanemab
The National Institute for Health and Care Excellence (NICE) has published further draft guidance for public consultation that continues to not recommend Alzheimer’s treatments donanemab and lecanemab for use on the NHS.
You can read more from NICE here: https://www.nice.org.uk/news/articles/second-consultation-launched-on-nhs-funding-for-alzheimer-s-treatments
We covered the 2024 licencing and NHS use announcements on lecanemab here: https://journalofdementiacare.co.uk/mhra-licence-lecanemab-for-use-in-the-uk. The most recent information relating to lecanemab use in Scotland is here: https://journalofdementiacare.co.uk/smc-reject-lecanemab-for-use-in-nhs-in-scotland
We covered the 2024 licencing and NHS use announcements on donanemab here: https://journalofdementiacare.co.uk/mhra-licence-donanemab